Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye

This study has been completed.

First Received: May 7, 2007 Last Updated: August 1, 2008 History of Changes

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00471419

Purpose

The purpose of this study is to see if Rimexolone (FID 109980) is a safe and effective treatment of dry eye.

Condition	Intervention	Phase
Dry Eye	Drug: Rimexolone	Phase III

Drug Information available for: Rimexolone

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry Eye

Further study details as provided by Alcon Research:

Primary Outcome Measures:

Secondary Outcome Measures:

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00471419

Locations

United States, Ohio
Cleveland
Cleveland, Ohio, United States, 44115

Sponsors and Collaborators

Alcon Research

Investigators

Study Director:

Michael Brubaker, PhD

Alcon Research

More Information

No publications provided

Study ID Numbers:	C-05-31
Study First Received:	May 7, 2007
Last Updated:	August 1, 2008
ClinicalTrials.gov Identifier:	NCT00471419 History of Changes
Health Authority:	United States: Food and Drug Administration

ClinicalTrials.gov processed this record on May 07, 2009